Replies to post #3388 on BANKRUPTCY PLAYS (CHAPTER)

[I Like Bottom Fishing]

09/15/2009 (16:15 ET) CRTX: Filed New Form 8-K, Material Event Disclosure - Edgar

http://www.knobias.com/individual/public/quote.htm?ticker=CRTX

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6515053

8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 9, 2009

Cornerstone Therapeutics Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware 000-50767 04-3523569
_____________________
(State or other jurisdiction _____________
(Commission ______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)

1255 Crescent Green Drive, Suite 250, Cary, North Carolina 27518
_________________________________
(Address of principal executive offices) ___________
(Zip Code)

Registrant’s telephone number, including area code: 919-678-6611

Not Applicable
______________________________________________
Former name or former address, if changed since last report



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 1.01 Entry into a Material Definitive Agreement.

On September 9, 2009, Cornerstone BioPharma, Inc. (the "Company"), a wholly owned subsidiary of Cornerstone Therapeutics, Inc. ("Cornerstone"), completed the previously announced acquisition from Oscient Pharmaceuticals Corporation ("Oscient") of the commercial rights to the antibiotic Factive® (gemifloxacin mesylate) in North America and certain countries in Europe, certain inventory and related assets. The United States Bankruptcy Court for the District of Massachusetts had approved the transaction on September 4, 2009.

In connection with the closing of the transaction, Oscient assigned to the Company the License and Option Agreement with LG Life Sciences, Ltd. related to Factive (as amended, the "Agreement"). The Agreement provides the Company with rights to commercialize gemifloxacin in North America, France, Germany, the United Kingdom, Luxembourg, Ireland, Italy, Spain, Portugal, Belgium, the Netherlands, Austria, Greece, Sweden, Denmark, Finland, Norway, Iceland, Switzerland, Andorra, Monaco, San Marino, Vatican City, Poland, Czech Republic, Slovakia, Slovenia, Hungary, Estonia, Latvia, Lithuania, Liechtenstein, Malta, Cyprus, Romania, Bulgaria, Croatia, Serbia and Montenegro, Bosnia and Herzegovina, Albania and the Former Yugoslav Republic of Macedonia.

The term of the Agreement will expire upon the termination or expiration in all of the countries covered by the license of the Company’s obligation to pay royalties on sales of Factive. The Company has the unilateral right at any time with 30 days’ prior notice to abandon its rights and obligations with respect to any country covered by the Agreement, or to terminate the Agreement in its entirety. In addition, either party may terminate the Agreement if the other party challenges the validity and/or enforceability of any of the party’s patent rights granted to the other party under the Agreement. The Agreement also provides certain termination rights to a party in connection with a material breach of the Agreement by the other party.

Under the terms of the Agreement, LG Life Sciences has agreed to supply and the Company is obligated to purchase from LG Life Sciences all of the Company’s anticipated commercial requirements for the Factive active pharmaceutical ingredient ("API"). LG Life Sciences currently supplies the Factive API from its manufacturing facility in South Korea.

Under the Agreement, the Company is responsible, at its expense and through consultation with LG Life Sciences, for the clinical and commercial development of gemifloxacin in the countries covered by the license, including the conduct of clinical trials, the filing of drug approval applications with applicable regulatory authorities in the Company’s territory and the marketing, distribution and sale of gemifloxacin in the Company’s territory.

The Company is obligated to pay a royalty on sales of Factive in North America and the territories covered by the license in Europe. These royalty obligations expire with respect to each country covered by the Agreement on the later of (i) the expiration of the patents covering Factive in such country or (ii) the expiration of data exclusivity in Mexico, Canada or the European Union respectively, or 2014 in the U.S.




Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cornerstone Therapeutics Inc.

September 15, 2009 By: /s/ David Price

Name: David Price
Title: Executive Vice President, Finance and Chief Financial Officer

http://www.knobias.com/individual/public/quote.htm?ticker=CRTX

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6515053

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6515053

News for OSCIQ News -- Lupin Expands Branded Play --Announces Acquisition of US Rights to ANTARA

Tuesday, September 29, 2009 4:45 PM

Scottrade.com
This email is compliments of Scottrade.com

News for 'OSCIQ' - (Lupin Expands Branded Play --Announces Acquisition of US Rights to ANTARA)

MUMBAI, India, Sept 29, 2009 /PRNewswire-FirstCall via COMTEX/ --
Pharmaceutical Major, Lupin Ltd. announced today the acquisition of US rights
for Antara(R) (Fenofibrate Capsules 43 mg and 130 mg). Lupin acquired the
product from Oscient Pharmaceuticals on September 25, 2009, under the procedures
of the U.S. Bankruptcy Court. Antara recorded net sales of US $ 70 million for
2008 (Source: IMS Dec 2008). Lupin paid $ 38.61 million for the product and
related assets inclusive of inventory.

Lupin had previously filed an ANDA for Fenofibrate Capsules 43 mg and 130 mg. On
September 21, 2009, prior to the acquisition of Antara(R), Lupin sold its ANDA
to Dr. Reddy's Laboratories. Lupin also settled and resolved the pending
litigation regarding the ANDA product.

Prior to the acquisition, Antara(R) was marketed by Oscient Pharmaceuticals.
Antara(R) has a strong brand equity with primary care physicians treating
patients for high LDL-C, Total-C, triglycerides, Apo-B and low HDL-C. The
Fenofibrate products market is $ 1.9 Billion for the last 12 months. Antara(R)
has 4.5% share of this market and grew 20 % in revenue this past year. Antara(R)
is prescribed for adjunct treatment of hypercholesterolemia (high blood
cholesterol) and hyper-triglyceridemia (high triglycerides) in combination with
diet.

The Antara acquisition enables Lupin to enter the primary care market with a
three product portfolio. Lupin's Suprax Tabs and Allernaze have strong potential
in primary care. Lupin will be more than doubling its sales force size in the
next 12 months to reach the key targets for the three products.

"We are very excited with our 2nd NDA acquisition within a span of 4 months. The
Antara(R) acquisition demonstrates Lupin's success in, and commitment to
building its brand franchise and equity in the US. It underlines Lupin's
differentiated strategy for the US market. Antara(R) is a step forward that will
help us strengthen and grow our brand business. Since Antara(R) is a previously
approved, commercial product, our sales and marketing efforts will commence
immediately and we are optimistic of it contributing positively to our topline
and bottomline in the coming quarters and years," said Vinita Gupta, Group
President & CEO, Lupin Pharmaceuticals Inc

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational
pharmaceutical company producing a wide range of quality, affordable generic and
branded formulations and APIs for the developed and developing markets of the
world. The Company today has significant market share in key markets in the
Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI,
Anti-Infectives and NSAIDs therapy segments, not to mention global leadership
positions in the Anti-TB and Cephalosporins. The Company's R&D endeavors have
resulted in significant progress in its NCE program. The Company's foray into
Advanced Drug Delivery Systems has resulted in the development of platform
technologies that are being used to develop value-added generic pharmaceuticals.

Our Drugs and products reach over 70 countries in the world. Today, Lupin has
the unique distinction of being the fastest growing top 10 Generics player in
the two largest pharmaceutical markets of the world -- The U.S. (ranked 9th by
prescriptions & growing at 92 %) and Japan (ranked 7th and growing at 23%). The
company is also the fastest growing, top 5 pharmaceutical player in India (ORG
IMS - March 2009) and the fastest growing Generic player in South Africa (ranked
6th and growing at over 30 % YoY - IMS)

For the financial year ended March 2009, Lupin's Consolidated Revenues and
Profit after Tax were Rs. 39,145 million and Rs. 5015 million respectively.





BSE: 500257 NSE: Lupin REUTERS: LUPN.BO BLOOMBERG: LPC IN






For further information contact:



Shamsher Gorawara

Head - Corporate Communications

Lupin Limited

[e-mail]

Mobile: [phone]



OR



Sonia Mansata

Text 100

[e-mail]

Mobile: [phone]



Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act
of 1995:

This release contains forward-looking statements that involve known and unknown
risks, uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Many of these risks, uncertainties and
other factors include failure of clinical trials, delays in development,
registration and product approvals, changes in the competitive environment,
increased government control over pricing, fluctuations in the capital and
foreign exchange markets and the ability to maintain patent and other
intellectual property protection. The information presented in this release
represents management's expectations and intentions as of this date. Lupin
expressly disavows any obligation to update the information presented in this
release.

SOURCE Lupin Limited



www.prnewswire.com


Copyright (C) 2009 PR Newswire. All rights reserved

-0-




KEYWORD: India

INDUSTRY KEYWORD: PHA

MTC

HEA

SUBJECT CODE: TNM

Source: Comtext Market News

[I Like Bottom Fishing]

Mattchew take a look at this post made by MaryKAustin, she has the Osciq chart play more correctly then I, on the OSCIQ chart play. She did a great Osciq chart play T/A and it was more like the SSCCQ chart play, I was close but she has it correct.

Please click here to view.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=42170115

God bless and always the best of trading.

[I Like Bottom Fishing]

Updated 10/15/2009 OSCIQ OSCIENT PHARMACEUTICALS CP Daily Commentary
http://www.americanbulls.com/StockPage.asp?CompanyTicker=OSCIQ&MarketTicker=OTC&TYP=S


http://www.americanbulls.com/StockPage.asp?CompanyTicker=OSCIQ&MarketTicker=OTC&TYP=S
Our system posted a WAIT today. The previous SELL recommendation was issued on 10.12.2009 (3) days ago, when the stock price was 0.0480. Since then OSCIQ has fallen -8.33% .

Our WAIT tag says all that is to say. Stay at cash or check the other stocks while waiting the next signal. Do not bother with buying or short selling this stock as long as the WAIT tag stays.
Data provided by: End of Day Data

WAIT

0.0440 
 +0.0020 	+4.76% 
 Candlestick Analysis 
 Today’s Candlestick Patterns: 
 Black Candlestick 
 	 
 Candlestick Pattern 
  
 Today a Black Candlestick was formed. This represents normal selling pressure. 
 For more about this candlestick click here. 
 http://www.americanbulls.com/StockPage.asp?CompanyTicker=OSCIQ&MarketTicker=OTC&TYP=S	  
   	 
 Stock Quote 
 Day's Close 	0.0440 
 Previous Close 	0.0420 
 Previous Open 	0.0430 
 Change 	+0.0020 
 % Change 	+4.76% 
 Volume 	320,152 
 	  	 
 Stock Activity 
 Day's Open 	0.0489 
 Day's High 	0.0489 
 Day's Low 	0.0420 
 20-Day Close M.A. 	0.0533 
 50-Day Close M.A. 	0.0540 
 65-Day Volume M.A. 	2,516,032 
 	  
 http://www.americanbulls.com/StockPage.asp?CompanyTicker=OSCIQ&MarketTicker=OTC&TYP=S 
 	 
 Two-Year Signal History 
 Date 	         Price 	  Signal 	$100 
 Became 
 10.12.09 	0.0480 	   Sell 		109 
 10.05.09 	0.0521 	   Buy 		118 
 09.09.09 	0.0640 	   Sell 		118 
 09.04.09 	0.0650 	   Buy 		120 
 08.26.09 	0.0750 	   Sell 		120 
 08.20.09 	0.0450 	   Buy 		72 
 08.05.09 	0.0305 	   Sell 		72 
 07.22.09 	0.0320 	   Buy 		75 
 07.06.09 	0.2100 	   Sell 		75 
 06.30.09 	0.1950 	   Buy 		70 
 06.10.09 	0.3899 	   Sell 		70 
 06.04.09 	0.3000 	   Buy 		54 
 05.05.09 	0.2000 	   Sell 		54 
 04.01.09 	0.1250 	   Buy 		34 
 03.10.09 	0.0900 	   Sell 		34 
 02.13.09 	0.2100 	   Buy 		79 
 01.07.09 	0.2700 	   Sell 		79 
 01.02.09 	0.1800 	   Buy 		52 
 12.29.08 	0.2000 	   Sell 		52 
 12.19.08 	0.1800 	   Buy 		47 
 12.01.08 	0.2700 	   Sell 		47 
 11.04.08 	0.6700 	   Buy 		117 
 10.24.08 	0.6400 	   Sell 		117 
 09.24.08 	0.7800 	   Buy 		143 
 08.18.08 	1.270 	   Sell 		143 
 08.06.08 	1.200 	   Buy 		135 
 07.31.08 	1.450 	   Sell 		135 
 07.22.08 	1.370 	   Buy 		127 
 07.08.08 	1.380 	   Sell 		127 
 07.01.08 	1.420 	   Buy 		131 
 06.27.08 	1.450 	   Sell 		131 
 06.25.08 	1.490 	   Buy 		135 
 06.06.08 	1.800 	   Sell 		135 
 05.28.08 	2.000 	   Buy 		150 
 05.15.08 	2.140 	   Sell 		150 
 05.12.08 	1.930 	   Buy 		135 
 05.07.08 	1.920 	   Sell 		135 
 04.24.08 	1.880 	   Buy 		132 
 03.10.08 	1.610 	   Sell 		132 
 02.11.08 	1.280 	   Buy 		105 
 01.25.08 	1.450 	   Sell 		105 
 01.11.08 	1.330 	   Buy 		96 
 12.13.07 	1.480 	   Sell 		96 
 11.30.07 	1.300 	   Buy 		85 
 11.28.07 	1.430 	   Sell 		85 
 11.09.07 	1.690 	   Buy 		100 
 10.12.07 	2.970 	   Sell 		100

http://www.americanbulls.com/StockPage.asp?CompanyTicker=OSCIQ&MarketTicker=OTC&TYP=S

BLACK CANDLESTICK


http://www.candlesticker.com/Cs05.asp

Type: Reversal/Continuation
Relevance: Indecision
Prior Trend: N/A
Reliability: Low
Confirmation: N/A
No. of Sticks: 1

http://www.candlesticker.com/Cs05.asp

Definition:

The Black Candlestick represents normal selling pressure.

Recognition Criteria:

1. The real body of this pattern is black with normal length.
2. The upper and lower shadows are smaller than the length of the real body.
Explanation:

Selling pressure is indicated by a Black Candlestick. The pattern shows that prices declined from open to close during the day and sellers were in control throughout this process.

Important Factors:

Like most other single candlestick patterns the Black Candlestick has low reliability. It reflects only one day's trading and can be interpreted both as a continuation and a reversal pattern. The pattern must be used with other candlesticks for a better or healthier confirmation of a trend.

http://www.candlesticker.com/Cs05.asp


http://www.americanbulls.com/StockPage.asp?CompanyTicker=OSCIQ&MarketTicker=OTC&TYP=S

































The opinions provided herein are intended to inform. They come with no warranty of any kind. If you should choose to interpret AmericanBulls.com information as investment advice, you do so at your own risk. Investing can be a very dangerous venture and it is you who must assume the entire cost and risk involved in all of your investment decisions, should you choose to follow this advice or use this information. AmericanBulls.com staff, members of the staff's families, and/or entities with which they are affiliated, may from time to time, buy, sell or hold stock in and have other financial dealings with the companies that appear on the AmericanBulls.com web site, mailings, or publications. The information contained on the AmericanBulls.com web site, mailings, and publications is drawn from sources believed to be factual and reliable, but in no way does AmericanBulls.com represent or guarantee the accuracy or completeness thereof, nor in providing it, does AmericanBulls.com assume any liability. This information is given as of the date appearing on the AmericanBulls.com web site report or mailing, and AmericanBulls.com assumes no obligation to update the information or advice on further developments relating to any named securities. The information found on the AmericanBulls.com web site, mailings, or publications is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the expressed, written consent of the editors.